NCT06888388

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

RecruitingOBSERVATIONAL

Trial Details

Start: 2025-02-01Est. Completion: 2027-02-01

Enrollment target: 4,700 participants

Locations

Yale University, New Haven, Connecticut, United States
Brigham and Women's Hospital - Dana-Farber Brigham Cancer Center, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
University of Rochester, Wilmot Cancer Institute, Rochester, New York, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Melbourne, Peter MacCallum Cancer Center, Melbourne, Australia
Ziekenhuis Aan de Stroom, Antwerp, Belgium
University of Calgary, Calgary, Alberta, Canada
Hamilton Health Sciences, Hamilton, Ontario, Canada
Women's College Hospital, University of Toronto, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
CHU de Quebec Université laval, Québec, Quebec, Canada
Cancer Institute Hospital of JFCR, Tokyo, Tokyo, Japan
Champalimaud Foundation, University of Lisbon, Lisbon, Portugal
Asan Medical Centre, Seoul, South Korea
Belfast Health & Social Care Trust, Belfast, United Kingdom

Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer

This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of …

Guangzhou, ChinaEst. completion Sep 15, 2028

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine Carcinoma

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.